Core Viewpoint - The article discusses the sudden popularity of the "climax needle," a cosmetic procedure aimed at enhancing female sexual pleasure, and highlights the associated marketing strategies and risks involved in its promotion [3][10]. Group 1: Market Dynamics - The "climax needle" gained significant attention on social media, leading to a surge in related medical beauty stocks, with companies like Tianyuan Co., Demei Chemical, and Bavi Co. seeing stock price increases of over 9% from April 25 to 27 [3]. - The domestic market for the "climax needle" reached 8.7 billion yuan in 2024, with projections to exceed 15 billion yuan in 2025 and potentially reach 80 billion yuan by 2030, reflecting a compound annual growth rate of over 35% [16][17]. Group 2: Marketing Strategies - The marketing of the "climax needle" follows a typical pattern in the medical beauty industry, leveraging emotional triggers such as "sexual anxiety" and "age crisis" to create a sense of urgency among women aged 30-45 [10][14]. - Social media platforms serve as the primary channels for promoting the "climax needle," with over 100,000 posts created to amplify its perceived benefits through user testimonials and before-and-after comparisons [10][14]. Group 3: Product and Safety Concerns - The "climax needle" involves injecting platelet-rich plasma (PRP) into the vaginal area, claiming to enhance sexual pleasure, but lacks substantial clinical trials to validate its effectiveness and safety [9][10]. - Medical professionals have reported various complications from the procedure, including infections, bleeding, and even severe cases leading to life-threatening conditions [9][10]. Group 4: Financial Implications - The "climax needle" boasts high profit margins, with a single injection costing around 10,000 yuan while the production cost is only about 1,000 yuan, resulting in a profit margin exceeding 80% [17]. - Companies are increasingly entering the "climax needle" market due to its lucrative nature, with significant interest from investors and businesses despite the lack of comprehensive clinical data supporting its claims [17][18].